Sanofi (SNY) Stock
NASDAQSNY has an Alpha Score of 38 out of 100 (weak), computed on Oct 26, 2026 from 3 of 4 sub-scores. 10 members of Congress disclosed 19 trades in SNY since 2017: 9 purchases and 10 sales, most recently Alan Armstrong (purchase, Mar 30, 2026). 5 of the hedge funds AlphaScala tracks reported SNY in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $159.03M. Its trailing P/E ratio is 22.8 and its net margin 8.1% (key statistics as of Oct 29, 2026).
What is SNY's Alpha Score?
How it works →Alpha Score of 38 reflects weak overall profile with poor momentum, moderate value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 26, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Sanofi (SNY)?
Most recent: Alan Armstrong (purchase, Mar 30, 2026); records start Mar 16, 2017.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Alan Armstrong R-OK · Senate | 2026-03-30 | purchase | $15k – $50k |
| Lisa McClain R-MI · House | 2025-09-11 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-08-04 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-07-22 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-06-17 | purchase | $1k – $15k |
| John James R-MI · House | 2024-09-04 | sale | $1k – $15k |
| John James R-MI · House | 2023-11-10 | purchase | $1k – $15k |
| Dan Goldman D-NY · House | 2023-07-10 | sale | $15k – $50k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all SNY political trades →Which hedge funds own SNY?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 3.73M | $159.03M | +8% |
| Citadel Ken Griffin | 1.85M | $79.02M | +24% |
| Point72 Steve Cohen | 820K | $34.98M | NEW |
| Bridgewater Associates Ray Dalio | 207K | $8.83M | NEW |
| Maverick Capital Lee Ainslie | 52K | $2.20M | +110% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are SNY's key statistics?
Key statistics as of Oct 29, 2026
How does SNY's valuation compare with the Healthcare sector?
| Metric | SNY | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 22.8 | 27.1 | 97 |
| Net margin | 8.09% | 5.48% | 139 |
| Return on equity | 5.63% | 6.84% | 158 |
| Dividend yield (payers) | 4.12% | 1.62% | 50 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
SNY price chart
Powered by TradingViewWhat does Sanofi do?
Sanofi American Depositary Receipt represents American Depositary Shares (ADS) of Sanofi, a leading French multinational pharmaceutical company. Each ADR corresponds to one-half of an ordinary share listed on Euronext Paris, providing U.S. investors convenient access to the company's equity through a sponsored Level II ADR program managed by J.P. Morgan Chase Bank as depositary, with EQ Shareowner Services as transfer agent. Sanofi focuses on researching, developing, manufacturing, and marketing a broad portfolio of prescription medicines, vaccines, and consumer healthcare products addressing major unmet medical needs in areas such as immunology, neurology, oncology, cardiovascular diseases, and rare diseases. The ADR program ensures holders receive dividends in U.S. dollars, with options for reinvestment, and voting rights at the annual general meeting. Founded in 1973 and headquartered in Paris, France, Sanofi American Depositary Receipt facilitates seamless participation for U.S. shareholders in this global biopharmaceutical leader's ongoing innovations and market presence.